Background: Endotracheal extubation is connected to airway and cardiovascular reactions that can result in tachycardia, hypertension, arrhythmias, myocardial ischemia, coughing, agitation, bronchospasm, increased haemorrhaging, and raised intracranial and intraocular pressure, all of which can be life-threatening, especially in weaker patients. These effects are observed to be attenuated by dexmedetomidine, a highly selective 2 adrenoreceptor agonist, which also provides a smooth extubation.
Aim: To evaluate the impact of dexmedetomidine following tracheal extubation on hemodynamic and ventilatory recovery.
Methods: 40 patients who matched the inclusion and exclusion criteria and were between the ages of 21 and 46 were divided randomly into two groups of 20 each for this comparative study. 90 ml of NS were given to one group, while 0.4 mg of Dexmedetomidine were given to the other. At various points throughout the entire operation, the hemodynamic parameters of the two groups were compared to check for any variations.
Results: Compared to the control group, the study group had better control over variables such mean arterial pressure, systolic blood pressure, diastolic blood pressure, and heart rate. It is the statistical significance (P < 0.002) that the extubation quality score differed between the control and dexmedetomidine groups (2.13 vs. 1.23). Cough was present in 14.27% of the study group but in 52.38% of the control group. The study population had considerably more Bradycardia and Hypertension.
Conclusion: Dexmedetomidine is administered just prior to extubation to guarantee a smooth procedure and to lessen cardiovascular reactions. Additionally, it offers sufficient postoperative sedation.
Key words: extubation, adrenoreceptor, dexmedetomidine, hemodynamic parameters
|
